Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings

Question of the Month

PlayCombination therapy in familial hypercholesterolaemia: what can we gain from novel agents? LDL cholesterol lowering and effects on plaque: what can we learn from INTENSITY-HIGH?
Professor John Chapman

Download Now: New Slide Deck Programme

Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.

Find out more »

Hot Topics

14th Closed Virtual Meeting of the Editorial Board of PCSK9 Forum


PCSK9 inhibition: The evolving treatment paradigm post-MI

Lowering of guideline-recommended LDL-C goals in the post-MI setting has implications for real-world practice. Here, PCSK9 Forum Editors discuss cases, using evidence from ODYSSEY OUTCOMES and FOURIER.

Greg Schwartz

Prof Gregory Schwartz uses data from ODYSSEY OUTCOMES to support management strategies.

Watch now

Robert Guigliano

Prof Robert Giugliano discusses evidence from FOURIER in the context of managing FH patients.

Watch now

From the Editors

Proof-of-concept: Gene-editing for PCSK9 inhibition

Prof. John Chapman, Pitié-Salpêtrière University Hospital, Sorbonne University, and National Institute for Health and Medical Research (INSERM), Paris, France.

Read the report


Other related reports:

DA-VINCI: Need to do better with LDL cholesterol management in practice in Europe

Pooled analysis highlights the promise of inclisiran

Inclisiran: Update on efficacy, dosing regimen, safety and COVT trial

Very low lipoprotein(a) and very low LDL cholesterol – are they safe?

Meet our Editorial Board

View all our Editorial Board Prof John ChapmanResearch Professor at the University of Pierre and Marie Curie Prof Henry GinsbergDirector, Irving Institute for Clinical and Translational Research Dr Michel FarnierClinician based at Point Medical, Dijon, France Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology